Therefore, targeting Hsp27, Hsp60, Hsp70, or Hsp90 with CRISPR/Cas9 to enhance the selectivity for target Hsps, and combining different Hsps inhibitors, could be promising strategies to improve the effectiveness of cancer therapy. This evidence concerns the gene HSP90AA1 and cancer.